AMED - アメディシス (Amedisys Inc) アメディシス

 AMEDのチャート


 AMEDの企業情報

symbol AMED
会社名 Amedisys Inc. (アメディシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Nursing Services  
業種 ヘルスケア施設_サ―ビス   医療関連(Health Care)
概要 事業概要 アメディシス(Amedisys Inc)はヘルスケアサービス企業である同社の事業は在宅医療、ホスピス、パーソナルケアおよびその他である。同社は在宅医療、ホスピスおよびパーソナルケアサービスの提供者である。同社の在宅医療事業は患者が手術・病気から回復し、慢性疾患に罹り、病院の再入院の防止をサポートする医療を提供する。ホスピス事業は終末期疾患の患者を支援する。パーソナルケア事業は患者に日常生活の不可欠な活動を支援する。   アメディシスは米国の在宅医療・ホスピスサ―ビスプロバイダ―。在宅医療部門は看護師、ナ―スプラクティショナ―、介護助手、理学療法士、作業療法士、言語療法士、医療ソ―シャルワ―カ―などを通じた在宅医療サ―ビス・プログラムを提供。ホスピス部門は末期患者とその家族に緩和医療を提供。米国とプエルトリコで事業を展開。   Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for its patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With ~21,000 employees, in 514 care centers in 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients in need every year.
本社所在地 3854 American Way Suite A Baton Rouge LA 70816 USA
代表者氏名 Paul B. Kusserow Paul B. Kusserow
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 225-292-2031
設立年月日 1982年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 17900人
url www.amedisys.com
nasdaq_url https://www.nasdaq.com/symbol/amed
adr_tso
EBITDA EBITDA(百万ドル) 148.16200
終値(lastsale) 116.85
時価総額(marketcap) 3720036833.7
時価総額 時価総額(百万ドル) 3784.027
売上高 売上高(百万ドル) 1595.266
企業価値(EV) 企業価値(EV)(百万ドル) 3882.728
当期純利益 当期純利益(百万ドル) 92.21800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amedisys Inc revenues increased 10% to $810.9M. Net income increased from $19.6M to $60.5M. Revenues reflect Home Health Care segment increase of 6% to $575.6M Hospice segment increase of 13% to $198.7M Personal care segment increase of 31% to $36.6M. Net income benefited from Other segment loss decrease of 31% to $65.8M Home Health Care segment income increase of 22% to $86.7M.

 AMEDのテクニカル分析


 AMEDのニュース

   7 Analysts Have This to Say About Amedisys  2022/04/29 13:24:44 Benzinga
Analysts have provided the following ratings for Amedisys (NASDAQ: AMED ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 1 3 1 0 0 According to 7 analyst offering 12-month price targets in the last 3 months, Amedisys has an average price target of $172.29 with a high of $200.00 and a low of $131.00. Below is a summary of how these 7 analysts rated Amedisys over the past 3 months. … Full story available on Benzinga.com
   Amedisys to Present at Multiple Healthcare Conferences in May  2022/04/29 12:00:00 GlobeNewswire
BATON ROUGE, La., April 29, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard, President and Chief Executive Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one on ones at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, at 5:40 p.m. ET, the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, and the UBS Global Healthcare Conference on Monday, May 23, at 9:15 a.m. ET.
   Amedisys, Inc. (AMED) CEO Christopher Gerard on Q1 2022 Results - Earnings Call Transcript  2022/04/28 21:45:11 Seeking Alpha
Amedisys, Inc. (NASDAQ:NASDAQ:AMED) Q1 2022 Earnings Conference Call April 28, 2022, 11:00 ET Company Participants Nick Muscato - Chief Strategy Officer Christopher Gerard - CEO, President…
   SQZ Biotechnologies, Amedisys top healthcare gainers; Teladoc, Align lead losers'' pack  2022/04/28 14:03:25 Seeking Alpha
SQZ Biotechnologies SQZ +20%. Amedisys (AMED) +7%. Teladoc Health TDOC -46%. Align Technology ALGN -23%.
   Amedisys, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:AMED)  2022/04/28 10:32:13 Seeking Alpha
The following slide deck was published by Amedisys, Inc.
   Amedisys to acquire Evolution Health, terms not disclosed (NASDAQ:AMED)  2022/02/02 13:25:02 Seeking Alpha
Amedisys (AMED) to acquire Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati
   Amedisys appoints Chris Gerard as CEO effective April 15, 2022  2022/01/10 13:31:27 Seeking Alpha
Amedisys (AMED) announced that Chairman and CEO Paul Kusserow will retire as CEO on April 15th, 2022. Upon his retirement as CEO, Mr
   United States At-Home Care Market Report 2021-2025 Featuring Kindred at Home, Amedisys, LHC Group, and Encompass Health Corp  2022/01/06 10:23:00 GlobeNewswire
Dublin, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The "The US At-Home Care Market: Size, Trends & Forecast with Impact of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com''s offering.
   Bank of America Corp DE Decreases Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)  2021/12/24 09:10:43 Dakota Financial News
Bank of America Corp DE reduced its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 13.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 345,377 shares of the health services providers stock after selling 54,172 shares during the quarter. Bank of []
   Barclays Lowers Amedisys (NASDAQ:AMED) Price Target to $213.00  2021/12/22 08:28:44 ETF Daily News
Amedisys (NASDAQ:AMED) had its price objective decreased by Barclays from $236.00 to $213.00 in a research note released on Tuesday morning, Analyst Ratings Network reports. Barclays currently has an overweight rating on the health services providers stock. AMED has been the topic of several other reports. SVB Leerink raised their target price on Amedisys from [] The post Barclays Lowers Amedisys (NASDAQ:AMED) Price Target to $213.00 appeared first on ETF Daily News .
   Bank of America Corp DE Decreases Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)  2021/12/24 09:10:43 Dakota Financial News
Bank of America Corp DE reduced its holdings in shares of Amedisys, Inc. (NASDAQ:AMED) by 13.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 345,377 shares of the health services providers stock after selling 54,172 shares during the quarter. Bank of []
   Barclays Lowers Amedisys (NASDAQ:AMED) Price Target to $213.00  2021/12/22 08:28:44 ETF Daily News
Amedisys (NASDAQ:AMED) had its price objective decreased by Barclays from $236.00 to $213.00 in a research note released on Tuesday morning, Analyst Ratings Network reports. Barclays currently has an overweight rating on the health services providers stock. AMED has been the topic of several other reports. SVB Leerink raised their target price on Amedisys from [] The post Barclays Lowers Amedisys (NASDAQ:AMED) Price Target to $213.00 appeared first on ETF Daily News .
   DekaBank Deutsche Girozentrale Sells 15,091 Shares of Amedisys, Inc. (NASDAQ:AMED)  2021/12/19 09:36:42 Transcript Daily
DekaBank Deutsche Girozentrale decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 80.0% in the 3rd quarter, Holdings Channel reports. The fund owned 3,782 shares of the health services providers stock after selling 15,091 shares during the quarter. DekaBank Deutsche Girozentrales holdings in Amedisys were worth $561,000 as of its most recent filing with []
   Amedisys (NASDAQ:AMED) Lowered to “C” at TheStreet  2021/12/14 15:34:42 Dakota Financial News
TheStreet cut shares of Amedisys (NASDAQ:AMED) from a b- rating to a c rating in a report released on Friday, TheStreetRatingsTable reports. Several other analysts have also recently weighed in on AMED. Royal Bank of Canada cut their price target on shares of Amedisys from $244.00 to $221.00 and set an outperform rating on the […]
   6,505 Shares in Amedisys, Inc. (NASDAQ:AMED) Purchased by Kestra Private Wealth Services LLC  2021/12/10 11:50:42 Transcript Daily
Kestra Private Wealth Services LLC bought a new position in Amedisys, Inc. (NASDAQ:AMED) during the 3rd quarter, Holdings Channel reports. The fund bought 6,505 shares of the health services providers stock, valued at approximately $970,000. Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Eubel Brady & []

 関連キーワード  (ヘルスケア施設_サ―ビス 米国株 アメディシス AMED Amedisys Inc)

 twitter  (公式ツイッターやCEOツイッターなど)